Mylan Pharmaceuticals Private Limited, the Indian subsidiary of Mylan Inc., has entered into an agreement with Gilead Sciences, under which it has been appointed the exclusive distributor of Sovaldi® (sofosbuvir 400mg tablets) and Harvoni®(ledipasvir 90mg/sofosbuvir 400 mg tablets) for the treatment of chronic hepatitis C, in India. Mylan expects to begin distribution of Sovaldi in India in Q2 2015. Sovaldi received regulatory approval in India in January 2015 – the first country in Asia to approve the medicine.
Mylan President Rajiv Malik said that Hepatitis C was a growing public health concern, and Mylan was proud to partner with Gilead for life-saving medications for the 12 million hepatitis C patients in India.
